DE2349186C2 - Arzneimittel zur Verbesserung der Zellatmung, der Herzmuskelleistung und der Hirnfunktion - Google Patents
Arzneimittel zur Verbesserung der Zellatmung, der Herzmuskelleistung und der HirnfunktionInfo
- Publication number
- DE2349186C2 DE2349186C2 DE2349186A DE2349186A DE2349186C2 DE 2349186 C2 DE2349186 C2 DE 2349186C2 DE 2349186 A DE2349186 A DE 2349186A DE 2349186 A DE2349186 A DE 2349186A DE 2349186 C2 DE2349186 C2 DE 2349186C2
- Authority
- DE
- Germany
- Prior art keywords
- blood
- heptaminol
- blood extract
- extract
- medicines
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000003814 drug Substances 0.000 title claims description 9
- 230000003925 brain function Effects 0.000 title claims description 4
- 229940079593 drug Drugs 0.000 title claims description 4
- 210000004165 myocardium Anatomy 0.000 title claims description 4
- 230000029058 respiratory gaseous exchange Effects 0.000 title claims description 4
- 239000003918 blood extract Substances 0.000 claims description 32
- LREQLEBVOXIEOM-UHFFFAOYSA-N 6-amino-2-methyl-2-heptanol Chemical compound CC(N)CCCC(C)(C)O LREQLEBVOXIEOM-UHFFFAOYSA-N 0.000 claims description 20
- 229960005402 heptaminol Drugs 0.000 claims description 15
- 239000000243 solution Substances 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 10
- 239000008280 blood Substances 0.000 claims description 8
- 210000004369 blood Anatomy 0.000 claims description 8
- 239000002156 adsorbate Substances 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- 244000309466 calf Species 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 3
- 238000000502 dialysis Methods 0.000 claims description 3
- 238000010790 dilution Methods 0.000 claims description 3
- 239000012895 dilution Substances 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 230000003389 potentiating effect Effects 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 description 21
- 230000000694 effects Effects 0.000 description 14
- 238000000034 method Methods 0.000 description 12
- JZNBMCOSOXIZJB-UHFFFAOYSA-N 6-amino-2-methylheptan-2-ol;hydron;chloride Chemical compound Cl.CC(N)CCCC(C)(C)O JZNBMCOSOXIZJB-UHFFFAOYSA-N 0.000 description 7
- 229960004344 heptaminol hydrochloride Drugs 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 230000008602 contraction Effects 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 239000000829 suppository Substances 0.000 description 5
- 239000008298 dragée Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 150000002381 heptaminols Chemical class 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229910002012 Aerosil® Inorganic materials 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 240000001879 Digitalis lutea Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000035508 accumulation Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- WNKCJOWTKXGERE-UHFFFAOYSA-N etifelmine Chemical compound C=1C=CC=CC=1C(=C(CN)CC)C1=CC=CC=C1 WNKCJOWTKXGERE-UHFFFAOYSA-N 0.000 description 2
- 229950005475 etifelmine Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- BIRSGZKFKXLSJQ-SQOUGZDYSA-N 6-Phospho-D-gluconate Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O BIRSGZKFKXLSJQ-SQOUGZDYSA-N 0.000 description 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 206010015856 Extrasystoles Diseases 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- YYDDKUSPJJPCCW-UHFFFAOYSA-N NCl(N)(N)(N)(N)(N)N Chemical compound NCl(N)(N)(N)(N)(N)N YYDDKUSPJJPCCW-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000000418 Premature Cardiac Complexes Diseases 0.000 description 1
- 241000270940 Rana temporaria Species 0.000 description 1
- 241000206572 Rhodophyta Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000529895 Stercorarius Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- IENXJNLJEDMNTE-UHFFFAOYSA-N acetic acid;ethane-1,2-diamine Chemical compound CC(O)=O.NCCN IENXJNLJEDMNTE-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 230000000059 bradycardiac effect Effects 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004098 cellular respiration Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 201000009101 diabetic angiopathy Diseases 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- -1 ester hydrochloride Chemical class 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000002276 neurotropic effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- SIXLXDIJGIWWFU-UHFFFAOYSA-N pyritinol Chemical compound OCC1=C(O)C(C)=NC=C1CSSCC1=CN=C(C)C(O)=C1CO SIXLXDIJGIWWFU-UHFFFAOYSA-N 0.000 description 1
- 229960004986 pyritinol Drugs 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000009974 thixotropic effect Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Zoology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH1673872 | 1972-11-16 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE2349186A1 DE2349186A1 (de) | 1974-05-22 |
| DE2349186C2 true DE2349186C2 (de) | 1982-11-11 |
Family
ID=4419791
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2349186A Expired DE2349186C2 (de) | 1972-11-16 | 1973-09-29 | Arzneimittel zur Verbesserung der Zellatmung, der Herzmuskelleistung und der Hirnfunktion |
Country Status (8)
| Country | Link |
|---|---|
| BE (1) | BE807455A (ref) |
| DE (1) | DE2349186C2 (ref) |
| ES (1) | ES420106A1 (ref) |
| FR (1) | FR2206941B1 (ref) |
| GB (1) | GB1391746A (ref) |
| IL (1) | IL43568A (ref) |
| NL (1) | NL149371B (ref) |
| SE (1) | SE419939B (ref) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU206367B (en) * | 1988-04-30 | 1992-10-28 | Sandoz Ag | Process for producing acid addition salts of steroid carboxylic acid-amidated taurine and glycine, as well as pharmaceutical compositions comprising such salts |
| DE19518156C2 (de) * | 1995-05-17 | 1997-05-07 | Alfons Dr Pfister | Verwendung von deproteinisiertem Hämodialysat |
| CN111295094A (zh) | 2017-10-09 | 2020-06-16 | 泰尔茂比司特生物技术有限公司 | 冻干容器及使用冻干容器的方法 |
| WO2020185916A1 (en) | 2019-03-14 | 2020-09-17 | Terumo Bct Biotechnologies, Llc | Lyophilization container fill fixture, system and method of use |
| CN116793783A (zh) * | 2023-05-26 | 2023-09-22 | 司法鉴定科学研究院 | 一种胶囊式含药生物基质冻干试剂及其制备方法与应用 |
-
1973
- 1973-09-29 DE DE2349186A patent/DE2349186C2/de not_active Expired
- 1973-10-23 GB GB4937973A patent/GB1391746A/en not_active Expired
- 1973-10-30 ES ES420106A patent/ES420106A1/es not_active Expired
- 1973-11-05 IL IL43568A patent/IL43568A/en unknown
- 1973-11-06 SE SE7315056A patent/SE419939B/xx unknown
- 1973-11-13 NL NL737315493A patent/NL149371B/xx not_active IP Right Cessation
- 1973-11-15 FR FR7340723A patent/FR2206941B1/fr not_active Expired
- 1973-11-16 BE BE137871A patent/BE807455A/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ES420106A1 (es) | 1976-03-16 |
| IL43568A0 (en) | 1974-03-14 |
| GB1391746A (en) | 1975-04-23 |
| NL149371B (nl) | 1976-05-17 |
| DE2349186A1 (de) | 1974-05-22 |
| NL7315493A (ref) | 1974-05-20 |
| SE419939B (sv) | 1981-09-07 |
| IL43568A (en) | 1976-05-31 |
| FR2206941B1 (ref) | 1977-09-02 |
| BE807455A (fr) | 1974-03-15 |
| FR2206941A1 (ref) | 1974-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69822665T2 (de) | Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14-dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen | |
| DE2813480C2 (de) | Arzneimittel-Depotpräparat vom Mehrfacheinheitsdosen-Typ | |
| DE69327585T2 (de) | Befruchtete muscheleier enthaltende zusammensetzung | |
| DE3137125C2 (ref) | ||
| DE69209414T2 (de) | Hirnaktivitätfördernde Zubereitungen | |
| DE2823174A1 (de) | Arzneimittel fuer die prophylaktische behandlung postoperativer tiefer venenthrombose | |
| DE69734163T2 (de) | Kiefernnadelextrakt sowie dessen verwendung | |
| DE3115080A1 (de) | Arzneimittel fuer die orale verabreichung und verfahren zu seiner herstellung | |
| DE69103624T2 (de) | Ipriflavone enthaltende pharmazeutische zubereitungen, verfahren zur herstellung und therapeutische verwendung. | |
| DE69937574T2 (de) | Verwendung des pharmazeutischen präparates "histochrome" zur behandlung des akuten herzinfarkts und ischämischer herzerkrankungen | |
| DE1915798A1 (de) | Arzneimittel gegen UEbersaeuerung | |
| DE3234537C2 (de) | Verwendung von 3-(2,2,2-Trimethylhydrazinium)propionatdihydrat zur Behandlung kardiovaskulärer Erkrankungen | |
| DE69835609T2 (de) | L-valine für lebererkrankungen | |
| DE69525348T2 (de) | Medikament gegen myotonische dystrophie | |
| DE3141970C2 (ref) | ||
| DE2013426A1 (en) | Zinc chelates of amino acids in diabetes | |
| DE2349186A1 (de) | Arzneimittel zur verbesserung der zellatmung, der herzmuskelleistung und der hirnfunktion und verfahren zu seiner herstellung | |
| DE68903448T2 (de) | Pharmazeutische und/oder diaetetische zusammensetzungen mit gehalt an l-carnitin und l-lysin. | |
| DE2131679A1 (de) | 3,4,5-Trimethoxybenzamidocarbonsaeure und ihre Salze sowie Arzneipraeparate | |
| AT330953B (de) | Verfahren zur herstellung eines pharmazeutischen praparates zur verbesserung der zellatmung | |
| DE2157201C3 (de) | Verbesserte feste orale Applikationsform von Raubasin | |
| EP0018550B1 (de) | Mittel zur Behandlung von Muskelerkrankungen | |
| DE1717100A1 (de) | Verfahren zur Herstellung von anticarcinomatoesen Praeparaten haemolytischer Streptococcen | |
| DE69313850T2 (de) | Veterinaerprodukt zur rehydration | |
| DE69925900T2 (de) | Prophylaktika und Heilmittel für Störungen der Darmschleimhaut |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| D2 | Grant after examination | ||
| 8327 | Change in the person/name/address of the patent owner |
Owner name: ELKAWI AG, ZUG, CH |
|
| 8327 | Change in the person/name/address of the patent owner |
Owner name: THYMOPHARMA AG, LUZERN, CH |